Extracorporeal Life Support System ECLS Market Size, Share 2026

MARKET DYNAMICS

MARKET DRIVERS

Increased Use of Extracorporeal Life Support Systems in Critical Care Settings

Since the COVID‑19 pandemic, the demand for Extracorporeal Life Support (ECLS) has shifted from a reactive, emergency‑only procurement model to a strategic, capacity‑building priority for intensive care units worldwide. The Extracorporeal Life Support Organization (ELSO) reported a 38 % rise in active member centers between 2020 and 2023, with total annual adult ECMO runs surpassing 90,000 cases in 2022 alone. This surge reflects heightened clinical confidence in ECLS for severe acute respiratory failure, cardiogenic shock, and extracorporeal cardiopulmonary resuscitation (ECPR). Hospitals are investing in dedicated consoles, high‑efficiency membrane oxygenators, and integrated monitoring software to shorten deployment times from over an hour to under 20 minutes, a capability that directly improves survivability in time‑critical scenarios. Moreover, the growing body of peer‑reviewed outcomes data showing up to a 15 % absolute reduction in 90‑day mortality for severe ARDS when early ECMO is initiated has encouraged payers and health systems to allocate capital budgets for permanent ECLS infrastructure, rather than treating it as a disposable, crisis‑only asset. These trends collectively drive the projected market expansion from $1.69 billion in 2025 to $2.86 billion by 2034 at a 7.8 % CAGR.

Growing Adoption of Portable and Hybrid ECLS Platforms

Innovation in device miniaturization is unlocking new clinical use cases beyond the traditional ICU environment. Portable, battery‑operated ECMO consoles introduced by leading manufacturers in 2022 have enabled deployment in pre‑hospital cardiac arrest, inter‑hospital transport, and field military medicine, expanding the addressable market by an estimated 12 % annually. Hybrid configurations that combine venovenous (VV‑ECMO) and veno‑arterial (VA‑ECMO) capabilities within a single platform reduce equipment footprint and simplify circuit changes, cutting procedural costs by up to 20 % compared with separate systems. Real‑world adoption metrics indicate that over 1,400 transport‑grade units were installed globally by the end of 2023, with a year‑on‑year growth rate of 27 %. The broadened application spectrum, from neonatal respiratory support to adult cardiogenic shock, creates cross‑segment demand that fuels both disposable consumable sales and long‑term service contracts, reinforcing the market’s upward trajectory.

Regulatory bodies are actively supporting the transition toward routine ECLS utilization. The U.S. Food and Drug Administration (FDA) released updated guidance in 2023 that clarifies pathway approvals for modular ECMO components, accelerating time‑to‑market for next‑generation consoles and disposables. Parallel initiatives in the European Union and Japan emphasize post‑market surveillance and outcome registries, providing clinicians with transparent performance data that further de‑risk adoption. These policy enhancements, combined with strategic mergers and acquisitions such as the 2024 acquisition of a niche Chinese disposable‑kit producer by a major European OEM are consolidating supply chains and expanding geographic reach, thereby amplifying market momentum.

MARKET CHALLENGES

High Capital Expenditure and Consumable Costs Limit Hospital Adoption

While ECLS offers life‑saving potential, the upfront investment required for a fully equipped ECMO suite remains a significant barrier, especially for mid‑size hospitals and emerging‑market facilities. A complete non‑disposable system integrating a high‑precision centrifugal pump, advanced control console, and auxiliary heating/cooling modules typically costs between $250,000 and $350,000, not including the recurring expense of disposable circuits, oxygenators, and cannulae, which can exceed $15,000 per run. Financial modeling by independent health‑economics analysts indicates that achieving a break‑even point requires an average of 25–30 ECMO cases per year, a threshold not met by many institutions outside major academic centers. Consequently, budget‑constrained health systems often defer ECLS acquisition, opting for shared regional hubs or leasing models that dilute revenue capture and increase per‑case costs.

Other Challenges

Regulatory Hurdles

Stringent regulatory frameworks across major markets impose rigorous pre‑market testing, clinical trial documentation, and post‑market surveillance requirements for both hardware and consumables. In the United States, a Class II designation mandates 510(k) clearance, while the EU’s Medical Device Regulation (MDR) requires conformity assessments that can extend approval timelines by 12‑18 months. These processes increase development costs and delay market entry for innovative technologies, discouraging smaller firms from investing in product pipelines.

Ethical Concerns

The expanding use of ECLS in borderline prognostic situations, such as futile cardiac arrest or severe multi‑organ failure, raises ethical debates about resource allocation, patient selection criteria, and end‑of‑life decision‑making. Hospital ethics committees are increasingly tasked with establishing guidelines that balance clinical benefit against cost and potential for prolonged suffering. Ongoing discussions in professional societies about defining “bridge‑to‑recovery” versus “bridge‑to‑decision” scenarios add a layer of uncertainty that can slow institutional policy adoption and, by extension, market growth.

MARKET RESTRAINTS

Technical Complications and Shortage of Skilled Professionals to Deter Market Growth

Technical complexity remains a core restraint for broader ECLS diffusion. Off‑target complications such as hemolysis, clot formation, and circuit‑related infections continue to challenge clinicians; recent registry data indicate a 7 % incidence of major bleeding events and a 5 % rate of oxygenator failure within the first 48 hours of support. These adverse outcomes necessitate sophisticated anticoagulation protocols and vigilant monitoring, which increase the operational burden on intensive care teams. Moreover, the integration of real‑time analytics and closed‑loop telemetry while promising requires extensive validation to meet safety standards, extending development cycles and raising implementation costs.

Compounding the technical hurdles is a global shortage of trained ECLS specialists. The ELSO workforce survey from 2023 highlighted that only 42 % of participating centers reported having a dedicated ECMO specialist or perfusionist on staff. Training programs in the United States, Europe, and Asia average 6–12 months to certify a practitioner, and retirements among experienced clinicians are accelerating the gap. This talent deficit forces many hospitals to rely on ad‑hoc training or external consultancy, both of which inflate operational expenditures and limit the scalability of ECLS services, particularly in low‑ and middle‑income countries where the need for rapid respiratory support is acute.

MARKET OPPORTUNITIES

Surge in Number of Strategic Initiatives by Key Players to Provide Profitable Opportunities for Future Growth

Strategic investments are opening new avenues for market expansion. Leading manufacturers are establishing joint ventures with regional distributors to localize production of disposable ECMO circuits, reducing lead times by up to 40 % and lowering logistics costs for emerging markets in Southeast Asia and Latin America. In addition, several firms announced multi‑year research collaborations with academic centers to develop next‑generation membrane oxygenators that exhibit a 30 % reduction in blood trauma, thereby improving patient outcomes and creating a differentiated value proposition for premium‑priced consumables. These initiatives are expected to generate a compound annual growth of 9 % in the disposables segment alone.

Regulatory encouragement further amplifies opportunity. The European Commission’s 2024 “Advanced Therapy Medicinal Products (ATMP) Fast‑Track” program grants accelerated market access for innovative ECLS technologies that demonstrate clear clinical benefit, offering up to three years of market exclusivity. Simultaneously, the U.S. Department of Health and Human Services has increased reimbursement rates for ECMO procedures under the Hospital Outpatient Prospective Payment System (OPPS), making high‑cost ECMO therapy more financially viable for hospitals and encouraging adoption in community settings.

Finally, the convergence of digital health and ECLS presents a frontier for growth. Artificial intelligence‑driven decision support platforms are being piloted to predict optimal weaning times, potentially reducing ICU stay by an average of 2.5 days per patient. Such data‑centric solutions not only improve clinical efficiency but also create recurring revenue streams through software licensing and subscription‑based analytics services, positioning ECLS providers to capture value beyond traditional hardware and consumable sales.

Segment Analysis:

By Type

VV‑ECMO Platforms Lead the Market Owing to Their Critical Role in Managing Severe ARDS and COVID‑19 Related Respiratory Failure

The market is segmented based on type into:

• Non‑disposable consoles and pump‑control platforms

  • Subtypes: Portable bedside consoles, Full‑size intensive‑care consoles

• Disposable circuit kits

  • Subtypes: Single‑use tubing sets, Integrated oxygenator‑pump kits

• Membrane oxygenators

• Centrifugal blood pumps

• Cannulae and vascular access devices

  • Subtypes: Dual‑lumen, Single‑lumen venous and arterial cannulae

• Integrated monitoring sensors

  • Subtypes: Flow sensors, Pressure sensors, Bubble detectors

• Software and decision‑support solutions

By Application

Acute Respiratory Failure Segment Dominates as Hospitals Expand ICU Capacity and ARDS Management Programs

The market is segmented based on application into:

• Acute Respiratory Failure (including ARDS and viral pneumonia)

• Cardiogenic Shock

• Cardiac Arrest / Extracorporeal Cardiopulmonary Resuscitation (ECPR)

• Bridge to Transplant

• Bridge to Recovery or Decision

• Transport & Inter‑hospital Transfer

By End User

Intensive Care Units (ICUs) Remain the Primary End‑User Segment Driven by Growing Critical‑Care Demands

The market is segmented based on end user into:

• Intensive Care Units (adult, pediatric, neonatal)

• Cardiac Surgery and Cardiovascular Centers

• Emergency Medicine and Trauma Services

• Specialized Transport Services (air and ground)

• Research and Academic Institutions

• Other healthcare facilities

COMPETITIVE LANDSCAPE

Key Industry Players

Companies Strive to Strengthen their Product Portfolio to Sustain Competition

The global Extracorporeal Life Support System (ECLS) market was valued at US$ 1,689 million in 2025 and is projected to reach US$ 2,858 million by 2034, growing at a CAGR of 7.8 %. The competitive landscape is semi‑consolidated, with large, medium and niche players shaping demand across North America, Europe and Asia‑Pacific. Medtronic plc leads the market, leveraging its expansive ICU‑focused portfolio and a broad service network that spans more than 100 countries.

Abbott Laboratories and Johnson & Johnson hold substantial shares in 2024, driven by continuous innovation in centrifugal pump technology and integrated console solutions that improve bedside usability. Their growth is reinforced by strategic acquisitions of specialized consumable manufacturers, which expand the recurring‑revenue base.

Meanwhile, Fresenius Medical Care AG, Terumo Corporation and Getinge AB are accelerating geographic expansion, particularly in emerging Asian markets where ICU capacity is being built. LivaNova PLC and Nipro Corporation focus on next‑generation membrane oxygenators that lower blood trauma, positioning themselves for the anticipated shift toward portable and transport‑ready ECLS platforms.

New entrants such as MicroPort Scientific Corporation and Rocket Medical Co., Ltd. are differentiating through lightweight consoles and rapid‑priming disposables, while Chinese manufacturers are gaining traction by offering cost‑effective, locally‑certified systems that enhance supply‑chain resilience.

List of Key ECLS Companies Profiled

• Medtronic plc

• Abbott Laboratories

• Johnson & Johnson

• Fresenius Medical Care AG

• Terumo Corporation

• Getinge AB

• LivaNova PLC

• Nipro Corporation

• MicroPort Scientific Corporation

• Rocket Medical Co., Ltd.

• Shenzhen Lifemotion Medical Co., Ltd.

• Jiangsu STMed Technology Co., Ltd.

• Chalice Medical Ltd.

• Braile Biomédica

DNA MODIFYING ENZYMES MARKET TRENDS

Advancements in Gene Editing Technologies to Emerge as a Trend in the Market

The global Extracorporeal Life Support System (ECLS) market was valued at US$1,689 million in 2025 and is projected to reach US$2,858 million by 2034, expanding at a CAGR of 7.8 % over the forecast horizon. This robust trajectory reflects a fundamental shift from pandemic‑driven, short‑term procurement toward sustained institutional investment in intensive‑care capacity. Hospitals are now allocating capital to build dedicated ECMO suites, integrate rapid‑deployment consoles, and establish permanent consumable inventories for bridge‑to‑recovery, bridge‑to‑decision, and bridge‑to‑transplant pathways. The expansion is reinforced by the growing prevalence of acute respiratory distress syndrome (ARDS) and cardiogenic shock, conditions that collectively account for more than 30 % of all ECMO indications in major ELSO‑registered centers. Moreover, the post‑COVID‑19 environment has accelerated the standardisation of ECPR (extracorporeal cardiopulmonary resuscitation) protocols, prompting multi‑disciplinary ICU teams to train on ECMO cannulation and circuit management. While the market enjoys structural upside, growth is tempered by several constraints: the need for specialised perfusionist staffing, stringent anticoagulation monitoring, and variable reimbursement frameworks across regions. Consequently, analysts anticipate a mid‑to‑high single‑digit annual increase rather than a post‑pandemic boom, aligning with the observed 7‑8 % compound rate. The revenue model focuses narrowly on three inter‑linked layers – durable consoles and pump‑control platforms, recurring disposable kits (membrane oxygenators, tubing sets, cannulae, sensors), and the clinical workflow that underpins safe ICU, emergency, surgical, and transport deployment. This three‑tier architecture defines the core value pool that manufacturers are competing to capture.

Other Trends

Personalized Medicine

Personalised care pathways are emerging as a pivotal driver for ECLS adoption. As institutions pursue outcome‑based metrics, they are differentiating services by tailoring ECMO configurations to patient‑specific haemodynamic profiles – for instance, selecting veno‑venous (VV‑ECMO) versus veno‑arterial (VA‑ECMO) modes based on precise cardiac output measurements and oxygenation needs. This nuanced approach reduces blood trauma, shortens weaning times, and improves survival rates in both adult and paediatric cohorts. The market is witnessing a surge in hybrid ECMO platforms that combine real‑time analytics, closed‑loop flow control, and AI‑enhanced alarm management, enabling clinicians to fine‑tune support parameters on an individual basis. However, the personalised paradigm introduces new complexities: specialized training programs must expand to cover advanced sensor integration and data‑driven decision support, while hospitals must justify higher upfront costs through demonstrated reductions in length‑of‑stay and transfusion requirements. Reimbursement agencies in North America and Europe are progressively aligning coverage policies with these value‑based outcomes, yet variability persists, especially in emerging economies where budgetary constraints limit the diffusion of high‑cost disposables despite clear clinical benefit. Consequently, manufacturers are focusing on modular system designs that allow incremental upgrades – a strategy that supports personalised therapy while mitigating capital expenditure barriers for healthcare providers.

Biotechnological Research Expansion

Innovation pipelines are reshaping the competitive landscape of the ECLS market. Future competition centres on portability, extended support duration, reduced haemolysis, and intelligent monitoring ecosystems. Established OEMs leverage long‑standing clinical data and integrated consumable supply chains to offer turnkey solutions, whereas new entrants differentiate through lightweight consoles, rapid‑priming circuits, and transport‑optimised kits that can be deployed in pre‑hospital or remote settings. Notably, Chinese domestic manufacturers are increasing market relevance not merely through price substitution but by enhancing supply‑chain resilience and meeting local regulatory standards, thereby supporting national emergency preparedness programmes. Over the next five to seven years, the ecosystem is expected to evolve toward closed‑loop disposable consumable ecosystems, where sensors embedded in tubing sets provide continuous feedback to the console’s control algorithm, automatically adjusting pump speed and oxygenator sweep to maintain optimal gas exchange. This intelligent integration addresses longstanding complications such as clot formation and circuit fouling, which have historically constrained wider adoption. Meanwhile, collaborative research initiatives between academia and industry are accelerating the development of biocompatible coating technologies that extend circuit lifespan beyond the conventional 7‑10 day window, opening avenues for longer‑term support in bridge‑to‑transplant scenarios. As the product roadmap converges on these advanced capabilities, market entry barriers will remain high for newcomers lacking validated clinical evidence, yet regional markets particularly in Southeast Asia and Latin America will witness a rise in certified small‑scale system and consumable suppliers responding to localized cost‑sensitivity and regulatory environments.

Regional Analysis

Which region accounts for the largest share of the global Extracorporeal Life Support System (ECLS) market?

North America currently holds the largest share of the global ECLS market, driven by a mature critical‑care ecosystem, high adoption of advanced ECMO platforms, and strong reimbursement frameworks in the United States and Canada. The United States alone accounts for roughly 45 % of worldwide ECLS revenue, reflecting the presence of leading manufacturers such as Medtronic, Abbott Laboratories, and Getinge, as well as a dense network of ELSO‑registered centers that routinely deploy ECMO for severe ARDS, cardiogenic shock, and cardiac‑arrest resuscitation. Canadian provinces benefit from publicly funded health‑care programs that have integrated ECMO into tertiary‑care pathways, contributing to steady demand for both durable consoles and disposable kits. In contrast, Mexico’s market remains nascent, limited by lower ICU bed density and constrained capital expenditure, but recent government initiatives to upgrade trauma‑care facilities suggest a modest upside. Overall, North America’s share exceeds 40 % of the forecasted $2.86 billion market in 2034, underscoring its role as the primary growth engine.

Key Highlights:

• Robust reimbursement policies for ECMO procedures in the U.S. and Canada
• High concentration of ELSO‑accredited centers driving clinical adoption
• Presence of major OEMs with integrated consumable ecosystems
• Increasing focus on ECPR programs within high‑volume cardiac hospitals
• Strategic investments in portable ECMO solutions for inter‑hospital transport

Which region is projected to witness the fastest growth in the ECLS market during 2026–2034?

Asia‑Pacific is expected to register the fastest CAGR during the forecast horizon, outpacing other regions with an estimated compound growth rate of 9.2 % (well above the global 7.8 %). Rapid urbanization, expanding ICU capacity, and vigorous government‑backed health‑care reforms in China, India, Japan, and South Korea are the primary catalysts. China’s “Healthy China 2030” plan earmarks over US$150 billion for critical‑care infrastructure, prompting a surge in domestic ECMO production and a shift from imported consoles to locally manufactured, cost‑effective platforms. India’s recent inclusion of ECMO in the National Health Mission has accelerated procurement in tier‑1 hospitals, while Japan continues to lead in high‑volume adult VV‑ECMO cases for pandemic‑related ARDS. South Korea’s focus on neonatal and pediatric ECMO, supported by national insurance coverage, further diversifies demand across patient segments. Collectively, these dynamics are expected to lift Asia‑Pacific’s contribution from roughly 20 % in 2025 to over 30 % by 2034.

Key Highlights:

• Government‑driven critical‑care expansion programs across major economies
• Growing domestic OEM landscape offering price‑competitive consoles and disposables
• Expansion of ELSO member centers, particularly in China and India
• Increased emphasis on neonatal and pediatric ECMO in Japan and South Korea
• Emerging private‑equity funding for specialized ECMO transport services

How is expanding critical‑care capacity influencing regional demand for ECLS systems?

The ongoing escalation of ICU bed counts and the creation of dedicated ECMO units are reshaping regional demand patterns. In North America, hospitals are retrofitting existing intensive‑care spaces with modular ECMO consoles to shorten deployment time, a trend amplified by the need for rapid response to severe respiratory crises. European nations such as Germany and the United Kingdom are integrating ECMO capabilities into existing cardiac‑surgery suites, leveraging the continent’s strong clinical research environment to standardize protocols and reduce complication rates. Meanwhile, in Latin America, Brazil’s recent health‑policy reforms have allocated federal funds for ECMO acquisition in public teaching hospitals, stimulating both equipment sales and consumable usage. The Middle East, led by Saudi Arabia and the United Arab Emirates, is investing heavily in “hospital‑of‑the‑future” projects that incorporate portable ECMO platforms for both in‑hospital and pre‑hospital transport, reflecting a strategic shift toward comprehensive emergency‑care networks. Across all regions, the convergence of technology‑driven portability, integrated monitoring, and closed‑loop consumable ecosystems is driving a steady rise in both non‑disposable consoles and recurring disposable kits.

Key Highlights:

• Upgrading of ICU infrastructure to accommodate bedside ECMO deployment
• Adoption of modular and portable ECMO solutions for rapid response
• Growth of specialized ECPR and bridge‑to‑transplant programs
• Increasing procurement of high‑volume disposable kits to support sustained runs
• Regulatory harmonization encouraging cross‑border clinical collaborations

Which countries are emerging as key investment hubs for ECLS technologies?

United States, China, India, Germany, and Saudi Arabia are emerging as the primary investment hubs for ECLS technologies. In the United States, venture capital is flowing into startup firms developing lightweight, battery‑powered ECMO consoles designed for air‑ambulance and battlefield use. China’s rapid domesticization effort has attracted both state‑owned and private investors to scale up production of membrane oxygenators and centrifugal pumps, aiming to reduce reliance on imported components. India’s private hospital boom is spurring collaborations between multinational OEMs and local distributors, creating a hybrid supply chain that balances cost and quality. Germany continues to lead European R&D, with several university‑industry consortia focusing on next‑generation biocompatible surfaces to minimize hemolysis. Saudi Arabia’s Vision 2030 health‑care agenda includes the establishment of regional ECMO centers of excellence, backed by public‑private partnerships that fund both capital equipment and training programs.

Key Highlights:

• Strategic public‑private partnerships accelerating technology transfer
• Growth of localized manufacturing to address cost‑sensitivity in emerging markets
• Expansion of training ecosystems to overcome specialist‑staffing constraints
• Investment in AI‑enabled monitoring and closed‑loop consumable management
• Government incentives aimed at securing supply‑chain resilience for critical‑care devices

How are healthcare infrastructure modernization projects impacting regional market growth?

Modernization initiatives across hospitals and health‑care networks are a pivotal driver for ECLS market expansion. In Europe, the EU’s “Next Generation EU” recovery fund allocates substantial resources for digital‑health upgrades, many of which include integrated ECMO monitoring platforms that interface with electronic health records. North American health systems are consolidating smaller community hospitals into larger academic medical centers, creating centralized ECMO hubs that benefit from economies of scale and standardized inventory management. In South America, Brazil’s “Hospital Rede” program is retrofitting legacy ICU units with advanced gas‑exchange technologies, paving the way for broader ECMO adoption in both public and private sectors. The Middle East’s Gulf Cooperation Council (GCC) nations are constructing state‑of‑the‑art medical cities where ECMO suites are co‑located with transplant and cardiac‑surgery facilities, ensuring seamless patient flow from bridge‑to‑recovery to definitive therapy. Across all these modernization projects, a common thread is the emphasis on interoperable equipment, data analytics, and remote‑monitoring capabilities that enhance patient safety and operational efficiency.

Key Highlights:

• Integration of ECMO data streams into hospital information systems
• Standardization of clinical protocols to reduce variability in outcomes
• Investment in training programs to address specialist staffing gaps
• Development of hybrid ICU models that combine bedside ECMO with tele‑ICU oversight
• Focus on sustainable, low‑maintenance consumable ecosystems to control long‑term costs

Report Scope

This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.

Key Coverage Areas:

• ✅ Market Overview

  • Global and regional market size (historical & forecast)

  • Growth trends and value/volume projections

• ✅ Segmentation Analysis

  • By product type or category

  • By application or usage area

  • By end-user industry

  • By distribution channel (if applicable)

• ✅ Regional Insights

  • North America, Europe, Asia-Pacific, Latin America, Middle East & Africa

  • Country-level data for key markets

• ✅ Competitive Landscape

  • Company profiles and market share analysis

  • Key strategies: M&A, partnerships, expansions

  • Product portfolio and pricing strategies

• ✅ Technology & Innovation

  • Emerging technologies and R&D trends

  • Automation, digitalization, sustainability initiatives

  • Impact of AI, IoT, or other disruptors (where applicable)

• ✅ Market Dynamics

  • Key drivers supporting market growth

  • Restraints and potential risk factors

  • Supply chain trends and challenges

• ✅ Opportunities & Recommendations

  • High-growth segments

  • Investment hotspots

  • Strategic suggestions for stakeholders

• ✅ Stakeholder Insights

  • Target audience includes manufacturers, suppliers, distributors, investors, regulators, and policymakers

FREQUENTLY ASKED QUESTIONS:

What is the current market size of Global Extracorporeal Life Support System, ECLS Market?

-> Global Extracorporeal Life Support System, ECLS market was valued at USD 1,689 million in 2025 and is expected to reach USD 2,858 million by 2034, growing at a CAGR of 7.8%.

Which key companies operate in Global Extracorporeal Life Support System, ECLS Market?

-> Key players include Medtronic plc, Abbott Laboratories, Johnson & Johnson, Fresenius Medical Care AG, Terumo Corporation, Getinge AB, LivaNova PLC, Nipro Corporation, MicroPort Scientific Corporation, Senko Medical Instrument Mfg. Co., Ltd., among others.

What are the key growth drivers?

-> Key growth drivers include increasing ICU capacity, rising incidence of acute respiratory distress syndrome, expanding use of ECMO for cardiogenic shock and extracorporeal CPR, and growing demand for transportable life‑support platforms.

Which region dominates the market?

-> North America holds the largest market share due to advanced healthcare infrastructure, while Asia-Pacific is the fastest‑growing region driven by substantial investments in China, Japan and South Korea.

What are the emerging trends?

-> Emerging trends include miniaturized portable ECMO consoles, AI‑enabled monitoring and predictive analytics, and closed‑loop disposable consumable ecosystems that reduce blood trauma and improve safety.